Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Neo-AEGIS: preliminary results of the Phase III RCT of CROSS versus perioperative chemotherapy

John V. Reynolds • 27 May 2021
ASCO 2021
Esophageal Cancer Gastric Cancer Gastroesophageal Cancer Gastrointestinal Cancer
Neo-AEGIS

John V. Reynolds, MD, St. James’s Hospital and Trinity College Dublin, Dublin, Ireland, discusses findings from the Neo-AEGIS study (NCT01726452), a Phase III neoadjuvant trial in adenocarcinoma of the esophagus and esophago-gastric junction cancer evaluating CROSS verses perioperative chemotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from John V. Reynolds

3:35
ENSURE: impact of surveillance after esophageal cancer surgery on quality-of-life
John V. Reynolds • 27 May 2021
3:07
Advances in esophageal cancer and unanswered questions
John V. Reynolds • 27 May 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals